Navigation Links
Biopharma in Medical News

PDL BioPharma Elects Barry Selick to Its Board of Directors

INCLINE VILLAGE, Nev., Aug. 3 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced the appointment of Harold E. ("Barry") Selick, Ph.D., to the Company's Board of Directors. "Barry's experience as a seasoned biotechnology executive and his extensiv...

PDL BioPharma Announces Second Quarter 2009 Financial Results

INCLINE VILLAGE, Nev., July 30 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today reported financial results for the second quarter ended June 30, 2009. Total revenues from continuing operations for the second quarter of 2009 were $125.9 million,...

PDL BioPharma to Announce Second Quarter 2009 Financial Results and Hold Conference Call July 30, 2009

INCLINE VILLAGE, Nev., July 22 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced that the company will hold a conference call and webcast on Thursday, July 30 at 4:30 p.m. Eastern Time to discuss its financial results for the second quarter of 200...

DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller

PRINCETON, N.J., July 7 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that it recently appointed Christopher P. Schnittker, CPA as its new Vice President of Administration and Controller. In th...

AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium

GAI-122, an investigational injectable nanoemulsion formulated with AlphaRx's proprietary drug delivery technology, providing significant neuro-protection in multiple in vitro and in vivo studies which suggest that this injectable nanoemulsion formulation has the potential to ...

Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF

AURORA, Ontario, June 23 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: HBP; OTCQX: HXBPF) announced today that it has commenced trading in the U.S. on the OTCQX International Market under the ticker symbol HXBPF. Investors can find real-time quotes, disclosure and financial informati...

AlphaRx and Gaia BioPharma Provide GAI-122 Development Update

GAI-122, an investigational injectable nano-emulsion formulated with AlphaRx's proprietary drug delivery technology, provides significant neuroprotection in animal behavioral models. Gaia BioPharma plans to initiate a clinical development program to further study GAI-122 for an ...

PDL BioPharma Announces Record Date for October 1 Dividend Payment

INCLINE VILLAGE, Nev., June 10 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced that all shareholders owning shares of PDL on September 17, 2009, will be paid a dividend of $0.50 per share on October 1, 2009. The Company previously announced that it would pay t...

The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate

CLINTON, N.J., May 27 /PRNewswire/ -- The Sage Group, a privately held international health care consulting group, announced today that HemispherX Biopharma has expanded the mandate for The Sage Group to include, in addition to the strategic partnering efforts related to Ampligen (an experimental ...

PDL BioPharma Appoints Karen J. Wilson as Vice President, Finance and Principal Accounting Officer

- Company Updates Board of Directors Audit Committee Members and Complies with Nasdaq Rule - INCLINE VILLAGE, Nev., April 29 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced that its board of directors has appointed Karen J. Wilson as vice president of fin...
Biopharma in Medical Technology

CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders

--Orally Active Enhancer of Human Nerve Growth Factor Has Demonstrated Promising Activity Preclinically-- --Broad Potential Applications Include Neuropathies, Alzheimer's and Huntington's Disease and Others-- RESEARCH TRIANGLE PARK, N.C., June 16 /PRNewswire/ -- CeNeRx BioPharma, Inc., a...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

PRINCETON, N.J., June 9 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that it has received Protocol Assistance feedback from the European Medicines Agency (EMEA) on the design of its confirmato...

Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.

SUNNYVALE, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Pharmacyclics (Nasdaq: PCYC ) announced today the close of a financing in connection with an investment by the principals of Pacific Biopharma Group, Ltd. (PBG), located in San Bruno California and Taizhou, Jiangsu Province, People's Republi...

Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand

NEWARK, Del., Dec. 3 /PRNewswire/ -- Isogen, a contract development and manufacturing organization for sterile filling, announced it has retained a strategic financial partner to help it expand operations to meet the global biopharma demand for Isogen's services. Isogen has previously anno...

Isogen Launches Major New Facility to Address Global Biopharma Demand

NEWARK, Del., Nov. 19 /PRNewswire/ -- Isogen, a contract development and manufacturing organization for sterile filling, today announced the first phase launch of its contract facility in Delaware. Isogen was founded to specifically address the process, facility and capacity problems commonly asso...

CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)

RESEARCH TRIANGLE PARK, N.C., Oct. 17 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today announced that it has initiated a Phase II clinical trial for its lead product candidate...

CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study

- State-of-the-Art PET Study Confirms Tyrima Exhibits Excellent Drug-Like Properties - - Results Support Initiation of Phase II Clinical Trials - RESEARCH TRIANGLE PARK, N.C., July 22 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing ...

Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation

LOS ANGELES, California, June 18 /PRNewswire-FirstCall/ -- Canopus BioPharma, Inc. (OTC: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer and addiction, today announced the signing of ...

CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)

- Tyrima Exhibits Excellent Safety Profile and Favorable Pharmacokinetics in Phase I Studies - RESEARCH TRIANGLE PARK, N.C., Jan. 16 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the...

Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy

- Helix BioPharma Corp. (TSX: HBP /Frankfurt: WKN 918864) AURORA, ON, March 5 /CNW/Dr. Heman Chao, Vice President of Research at Helix BioPharma Corp., a developer of novel cancer therapeutics, will be presenting a scientific poster at the Fourth International Conference on Tumor Microenvi...

More>>

Biopharma in Biological News

Biodegradable polymers show promise for improving treatment of acute inflammatory diseases

... and Robert Pierce, currently head of anatomic pathology at Schering-Plough biopharma Schering-Plough biopharma and formerly of the University of Rochester Medical Center, are collaborati...

OHSU turns innovations into commercial opportunities at record pace

...formation about Molecular MD, go to http://www.molecularmd.com ] ID biopharma which was spun off by Virogenomics Inc., an earlier OHSU startup -- was c...hnology and pharmaceutical companies in focusing on infectious diseases. ID biopharma will function as the commercialization accelerator for the Oregon Translati...

Intelligent materials to regenerate bone tissue

...nerate in such a way that it carries out similar functions as in its natural state. From Spain the Institute of Biomechanics of Valencia and Progénika biopharma S.A. are also participating. In the case of substantial deterioration of the bone, it may be necessary for the implant to provide both functional...

Ocean virus identified in human blood samples

...ys available to test for Vesivirus infection or antibodies, researchers say, that have been developed at OSU and licensed to private industry. "AVI biopharma has investigated their proprietary NeuGene antisense as an anti-Vesiviral treatment, and is currently conducting further research and development," sa...

Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned

... the United States and Europe. The CDC classifies ricin as a "Category B" biological agent, which means it is "relatively easy to disseminate." DOR biopharma has received an exclusive license for RiVax and is developing large scale manufacturing processes. DOR officials hope to produce a large stockpile for...
Biopharma in Biological Technology

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

PRINCETON, N.J., Aug. 4 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc., (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted Or...

PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009

INCLINE VILLAGE, Nev., July 29 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the BMO Capital Markets Healthcare Conference in New York City on Wednes...

DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology

PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that it has received a European patent which addresses its Lipid Polymer Micelle (LPM(TM)) technology for the improved oral...

Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease

EXTON, Penn., July 1 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of can...

DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation

PRINCETON, N.J., June 29 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that investigators at the Fred Hutchinson Cancer Research Center, Seattle, Washington, published a paper this morning...

KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)

DURHAM, N.C., June 24 /PRNewswire/ -- KBI Biopharma, Inc. (KBI) announced today that it has started the process of performing cell line generation with Crucell's PER.C6(R) human cell line platform, pursuant to the Agreement announced by Crucell, The Netherlands, on May 6, 2009. Under that agreemen...

Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference

AURORA, Ontario, June 19 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: HBP) today announced that Dr. Heman Chao, chief scientific officer at Helix BioPharma Corp., will be presenting a scientific poster describing L-DOS47 analytical method development findings at the 2009 American Ass...

Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy

TROMS0, Norway and SEOUL, Korea, June 19 /PRNewswire/ -- The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax today announced the signing of a collaborative agreement to test lead compounds LTX-315 and GV1001 as a combination therapy for the treatment of cance...

Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies, Inc.

FORT WORTH, Texas, June 16 /PRNewswire/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (WNDM.OB), announced today that it has reached an agreement in principle to acquire BioPharma Management Technologies, Inc., a privately held biotechnology company with a pl...

Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update

AURORA, Ontario, June 15 /PRNewswire/ -- Helix BioPharma Corp. ("Helix" or the "Company"), (TSX, FSE: "HBP") today announced its product development progress, quarterly highlights and financial results for the third quarter of fiscal 2009, ended April 30, 2009. THIRD QUARTER HIGHLIGHTS AND P...
Biopharma in Biological Products

ELISA Biopharma from Tecan

Description: Tecan has 20 years of expertise in the field of Enzyme-Linked Immunosorbent Assays (ELISA), and still offers the most powerful systems on the market. Freedom EVO easily manages up to 40 000 in-microplate tests requiring incubation and washing steps. The integration of different modules (such as w...
Company:Tecan
Other Tags
(Date:8/21/2014)... 21, 2014 August 11: – Robin ... own life by hanging, likely due to long-term depression. ... the foremost BioAcoustic Vocal Profiling investigator, appeared on the ... concerning Williams’ death; hoping to help people understand why ... to Williams’ suicide were proposed in terms of BioAcoustic ...
(Date:8/21/2014)... DoudouneCanadienneGoosePasCher.fr, one of the most popular suppliers of ... selection of Trillium Parkas for 2014. Moreover, the company’s ... and comfortable items are available at discounted prices, up ... September 01. , The CEO says happily, “We ... Trillium Parkas for new and old customers. The ...
(Date:8/21/2014)... 21, 2014 The costs for maintaining pet health ... according to new insurance industry studies. The Quotes Pros company is ... locate affordable plans from all 50 states at http://quotespros.com . ... $50 for a routine visit or complex surgery can use the ... of the system will be asked to provide a zip code ...
(Date:8/21/2014)... Heights, MI (PRWEB) August 21, 2014 ... emails informing a taxpayer that their federal tax payment ... email domain appears to come from the IRS, “tax@irs.gov”, ... victims to provide personal and financial information. , While ... years now, an uptick in phishing activity is occurring ...
(Date:8/21/2014)... many people, finding motivation to exercise is a challenge. Thankfully, ... approach of Zombies, Run!one of more than 31,000 health and ... growing number of apps that use games to increase physical ... fitness app makers looking to cash in to help people ... exercise remains to be seen. , "It,s just been assumed ...
Breaking Medicine News(10 mins):Health News:Robin Williams: What he could not bear to face 2Health News:Robin Williams: What he could not bear to face 3Health News:Fashionable And Comfortable Canada Goose Trillium Parkas For Sale At DoudouneCanadienneGoosePasCher.fr 2Health News:Pet Insurance Finder for 50 States Launched at Insurance Website Online 2Health News:Beware Of Phony “Tax Payment Rejected” IRS Emails 2Health News:Playing hunger games: Are gamified health apps putting odds in your favor? 2
(Date:8/20/2014)... 158 pregnant teenagers in Rochester, NY, nearly half engaged ... ice, cornstarch, vacuum dust, baby powder and soap, and ... Moreover, such teens had significantly lower iron levels as ... , Pregnant teens, regardless of pica, are at higher ... deficiency and anemia. Low iron in pregnant teens raises ...
(Date:8/20/2014)... in this image of the Para and Mato Grosso ... likely intentionally set in order to deforest the land. ... of trees where the land is thereafter converted to ... forestland to farms, ranches, or urban use. The herringbone-patterned ... Amazon Rainforest in the middle of the image are ...
(Date:8/20/2014)... When are athletes who have suffered concussions ready to ... has found that high school athletes who head back ... experience a significant regression in their abilities to simultaneously ... as seen in changes in their balance and/or altered ... Ten of the 12 had returned to activity in ...
Breaking Biology News(10 mins):Pica in pregnant teens linked to low iron 2Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
Other Contents